Helsinn Therapeutics (U.S.), Inc. was founded in 2009 and is located in New Jersey, USA. It was founded through an acquisition of a small R&D-focused biotech company and over the years has evolved into an integrated specialty pharmaceutical company focused on oncology and rare disease. Helsinn Therapeutics (U.S.), Inc. maintains a fully integrated commercial and medical organization within the US, with a portfolio of products in oncology therapeutics and supportive care. Since 2013, Helsinn Therapeutics has deployed a specialty sales force, a market access team and a field medical team and has been responsible for the commercialization of Aloxi® , Akynzeo® (oral and i.v.) and Valchlor® . In addition, Helsinn has participated in several co-promotions for oncology therapeutics. As Helsinn Therapeutics (U.S.), Inc. continues to grow and evolve, we remain committed to improving care for patients through our work to commercialize cancer therapeutics and cancer supportive care agents.